Lv1
40 积分 2024-05-31 加入
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
29天前
已完结
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
29天前
已关闭
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
1个月前
已完结
The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention
1个月前
已完结
CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer
1个月前
已完结
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
3个月前
已完结
Lesion Absorbed Dose–Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy
6个月前
已关闭
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
7个月前
已完结
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
7个月前
已完结
皖公网安备34019202002308
